EZH2 and breast carcinoma: EZH2 inhibitors and CM from EZH2 inhibitor-treated cells activated TAMs towards M2 polarization in vitro and in vivo, which might help us understand why EZH2 inhibitors do not achieve benefits in preclinical breast cancer models.